Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

NURS 142 > Module 7 Pharmacology - Anti-inflammatory/Anti-infective/Antibiotics > Flashcards

Module 7 Pharmacology - Anti-inflammatory/Anti-infective/Antibiotics Flashcards

1
Q

aspirin

Onset: 5-30 min
Peak: 1-3 hr
Duration: 3-6 hr

  1. Therapeutic and pharmacologic class (2,1)
  2. Indications (2)
  3. Contraindications (2)
  4. Antidote (4)
  5. Mechanism of action (1)
  6. Common and life-threatening side effects (3,3)
  7. Assessment and safety (3)
A

Trade Names: ASA, acetylsalicylic acid
Ther. Class.: antipyretic, nonopioid analgesic
Pharm. Class.: salicylate

Indications:

  • Inflammatory disorders (RA, OA)
  • Fever

Contraindications:

  • Bleeding disorders or thrombocytopenia
  • Hypersensitivity

Mechanism of Action:
-Inhibits production of prostaglandins

Therapeutic Effect:

  • Reduces inflammation
  • Reduces fever

Route: PO, rectal

Most Common Side Effects:
GI: dyspepsia, epigastric distress, nausea

Life-threatening Adverse Reactions:
GI: GI BLEEDING
Misc: ANAPHYLAXIS, LARYNGEAL EDEMA

Antidote/Emergency Treatment:

  • Activated charcoal
  • Stomach pump may be considered if overdose taken within 1 hour of treatment
  • IV D5W (to increase urine output)
  • Sodium bicarbonate (to increase urine pH, thereby increasing ASA elimination in urine)

Safety/Monitoring:

  • Those with asthma, allergies, and nasal polyps are at increased risk for hypersensitivity reaction
  • Those allergic to tartrazine are at increased risk for hypersensitivity reaction
  • Monitor for signs of toxicity (tinnitus, headache, altered mental state, hyperventilation, diaphoresis)

Interactions:

  • Increased risk of bleeding with heparin-like agents and thrombolytic agents
  • Increased risk of GI irritation with use of other NSAIDs
  • Ibuprofen may negate cardioprotective antiplatelet effect of low-dose ASA
  • May reduce effect of diuretics and ACE inhibitors

Metabolism and Excretion:

  • Metabolized by liver
  • Excreted mainly through kidneys (depends on urine pH)

Evaluation/Desired Outcomes:
-Increased joint movement (may take 2-3 weeks for max effect)

Patient Education:

  • Caution patient to avoid alcohol with this medication to lower risk of GI bleed (no more than 3 glasses/day)
  • Caution patient to avoid concurrent use of acetaminophen or other NSAIDs unless instructed by provider
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

naproxen

Taken for anti-inflammatory effect…
Onset: 2 weeks
Peak: 2-4 weeks
Duration: ?

  1. Therapeutic and pharmacologic class (3,0)
  2. Indications (2)
  3. Contraindications (5)
  4. Antidote/Emergency Treatment (2)
  5. Mechanism of action (1)
  6. Common and life-threatening side effects (6,4)
  7. Assessment and safety (3)
A

Trade Names: Aleve, Naprosyn
Ther. Class.: NSAID, antipyretic, nonopioid analgesic
Pharm. Class.: none

Indications:

  • Inflammatory disorders (RA, OA)
  • Fever

Contraindications:

  • Hypersensitivity and cross sensitivity to other NSAIDs
  • Active GI bleed
  • Ulcer disease
  • Periop pain control surround CABG
  • Nursing mothers

Mechanism of Action:
-Inhibits prostaglandin synthesis

Therapeutic Effect:

  • Suppress inflammation
  • Reduce fever

Route: PO

Most Common Side Effects:
CNS: dizziness, drowsiness, headache
GI: constipation, dyspepsia, nausea

Life-threatening Adverse Reactions:
CV: HF, MI, CVA
GI: DRUG-INDUCED HEPATITIS, GI BLEED
Misc: ANAPHYLAXIS, STEVENS-JOHNSON SYNDROME

Antidote/Emergency Treatment:

  • Follow protocol for NSAID overdose
  • Activated charcoal
  • Due to high protein binding, hemodialysis is not effective; alkalization of urine may be effective if done within 4 hours of overdose

Safety/Monitoring:

  • Those with asthma, aspirin allergy, and nasal polyps are at increased risk for hypersensitivity reaction
  • Assess for rhinitis, asthma, and urticaria
  • Assess ROM 1-2 hours after administration

Interactions:

  • Concurrent use with aspirin may decrease effectiveness
  • Increased risk of bleeding with anticoagulant/antiplatelet drugs
  • Adverse GI side effects with aspirin, corticosteroids, NSAIDs, or alcohol
  • May decrease effectiveness of antihypertensives and diuretics
  • May increase risk of hypoglycemia with insulin

Metabolism and Excretion:
-Mostly metabolized by liver

Evaluation/Desired Outcomes:

  • Improved joint mobility in 2-4 weeks
  • Reduction of fever

Patient Education:

  • Caution patient to avoid concurrent use of alcohol, aspirin, acetaminophen or other OTC meds without consulting a health care professional
  • Higher doses won’t increase therapeutic effect, but may increase side effects
  • For rapid effect, take 30 minutes before or 2 hours after meal; to decrease GI side effects, take with meal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ibuprofen

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

ketoralac

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

hydrocortisone

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

methylprednisolone

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

prednisone

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

triamcinolone

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

alcohol

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

povidone-iodine

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

chlorhexidine

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

hydrogen peroxide

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ampicillin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

dicloxacillin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

cephalexin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

cefuroxime

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

ceftriaxone

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

cefepime

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

ceftaroline

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

tetracycline

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

21
Q

doxycycline

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

22
Q

erythromycin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

23
Q

azithromycin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

24
Q

gentamicin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

25
Q

sulfamethoxazole with trimethoprim

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

26
Q

silver sulfadiazine

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

27
Q

ciprofloxacin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

28
Q

levofloxacin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

29
Q

vancomycin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

30
Q

metronidazole

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

31
Q

bacitracin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

32
Q

neomycin/polymyxin B/bacitracin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

33
Q

rifampin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

34
Q

linezolid

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

35
Q

telithromycin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

36
Q

daptomycin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

37
Q

imipenem-cilastatin sodium

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

38
Q

piperacillin with tazobactam

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

39
Q

quinupristin with dalfopristin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

40
Q

ampicillin sodium with sulbactam sodium

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

41
Q

ticarcillin disodium with clavulanate potassium

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

42
Q

amphotericin B

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

43
Q

fluconazole

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

44
Q

itraconazole

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

45
Q

voriconazole

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

46
Q

silver (e.g. silver dressings)

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

47
Q

collagenase

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

48
Q

becaplermin

Onset
Peak
Duration

  1. Therapeutic and pharmacologic class (#)
  2. Indications (#)
  3. Contraindications (#)
  4. Antidote (#)
  5. Mechanism of action (#)
  6. Common and life-threatening side effects (#)
  7. Assessment and safety (#)
A

Trade Names:
Ther. Class.:
Pharm. Class.:

Indications:

Contraindications:

Mechanism of Action:

Therapeutic Effect:

Route:

Most Common Side Effects:

Life-threatening Adverse Reactions:

Antidote:

Safety/Monitoring:

Interactions:

Metabolism and Excretion:

Evaluation/Desired Outcomes:

Patient Education:

NURS 142 (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions